Synthomer Enters £50m Related-Party Receivables Deal for Covenant Headroom

Synthomer taps KLK for £50m receivables purchase to boost year-end covenant headroom

Synthomer has struck a temporary receivables purchasing arrangement with Rainbow State Limited, a subsidiary of its largest shareholder Kuala Lumpur Kepong Berhad Group (KLK). KLK will buy around £50 million of Synthomer trade receivables that fall due on or before 28 February 2026.

The move is designed to give the group short-term financial flexibility and ensure a prudent level of banking covenant headroom at year end. The company says terms are on an arms-length basis and consistent with what third-party financiers would offer for a deal of this type.

How the receivables deal works and why it matters

A receivables purchase is a form of working capital finance: the company sells invoices it is owed by customers to a financier for cash today. That brings cash forward and reduces reported receivables, which can help liquidity and improve certain year-end banking metrics.

Synthomer already runs a committed €200 million non-recourse receivables facility. “Non-recourse” means the financier, not Synthomer, bears the credit risk of customer non-payment on those receivables. Some invoices are not eligible for that existing facility; this new KLK-backed arrangement covers a portion of those non-eligible receivables.

Interaction with the existing €200m receivables facility

Importantly, Synthomer expects the total receivables financed between the KLK arrangement and its existing facility to remain within €200 million (c.£175 million). In other words, this looks like a re-mix to include invoices that couldn’t be financed in the existing structure, rather than a step-change increase in overall receivables financing.

That nuance matters: it points to balance sheet housekeeping to navigate year-end covenants, not an aggressive expansion of off-balance-sheet financing.

Related party transaction: safeguards and process

KLK and connected parties own around 27% of Synthomer, making KLK a related party under the UK Listing Rules. Related party transactions require additional governance. The board – excluding Dato’ Lee Hau Hian and Uwe Halder due to their relationship with KLK – has concluded the arrangement is fair and reasonable for shareholders.

Rothschild & Co, acting as sponsor, has advised the board to that effect. The company also emphasises the terms are arms-length – finance-speak for comparable to what independent market players would accept.

Banking covenants, headroom and the year-end focus

Banking covenants are tests lenders set – often around leverage, interest cover, or minimum liquidity. “Headroom” is the cushion before breaching those tests. By bringing in cash from receivables sales, Synthomer increases that cushion at the reporting date.

The RNS makes clear this is a temporary, year-end measure to keep prudent headroom. That’s sensible risk management. It does, however, flag that covenants and working capital are in sharp focus as the year closes.

Key numbers at a glance

New receivables purchase	c.£50 million
Buyer	Rainbow State Limited (KLK subsidiary)
Receivables due by	On or before 28 February 2026
Existing receivables facility	€200 million, non-recourse
Total expected receivables financed	Not to exceed €200 million (c.£175 million)
KLK shareholding	c.27%
Purpose	Short-term financial flexibility and prudent year-end covenant headroom
Commercial terms	Arms-length; consistent with third-party market terms
Post-close trading update	Late January

Positives and watch-outs for shareholders

What looks positive

• Pragmatic cash management: converting receivables to cash at year end supports liquidity and covenant headroom without equity dilution.
• No expansion in total receivables financing: management does not expect the combined use of facilities to exceed €200 million, which signals discipline.
• Governance checks in place: conflicted directors recused and an external sponsor opined the deal is fair and reasonable.

What to keep an eye on

• Why certain invoices are ineligible for the non-recourse facility is not disclosed. That’s normal in practice but worth noting as a data gap.
• Related party optics: even at arms-length, some investors prefer third-party financing. The board has addressed this through process and pricing assurances.
• Underlying trading and covenant headroom: the late-January post-close update should bring colour on the year-end position and how temporary this support proves to be.

Upcoming catalyst: late-January trading update

Synthomer plans to issue a post-close trading update in late January for the year ending 31 December 2025. Expect commentary on trading and the year-end balance sheet position. Investors will be looking for clarity on cash generation, working capital movements and covenant headroom after taking this receivables step.

My take: sensible short-term flexibility, with balance sheet discipline

This is a neat, targeted tool to navigate year-end covenants without stretching the overall receivables financing envelope. Keeping the combined facilities within €200 million feels conservative, and the arms-length assurance helps counter related party concerns.

On balance, I see this as a modest positive for financial flexibility, paired with a reminder that covenants remain a live consideration. The late-January update now carries extra weight as the moment to show that this was a precaution rather than a pressure signal.

Brief company snapshot for context

Synthomer is a leading supplier of high-performance, specialised polymers across coatings, construction, adhesives, and health and protection. The group employs around 3,800 people, operates five innovation centres and 29 manufacturing sites across Europe, North America, the Middle East and Asia, and serves more than 6,000 blue-chip customers.

Continuing revenue was £2.0 billion in 2024. The business is organised into three divisions: Coatings & Construction Solutions, Adhesive Solutions, and Health & Protection and Performance Materials. The company highlights innovation and sustainability, with around 20% of sales volumes from new and patent-protected products and 2030 decarbonisation targets approved by the Science Based Targets initiative.